Table 4.
Spitzoid and Spitz-Related Melanomas
| Sex/Age, y | Follow-up, mo | Location | Pathologic Finding | SLNB | Additional Treatment | Status at Last Follow-up |
|---|---|---|---|---|---|---|
| M/11 | 115 | R shoulder | Spitzoid melanoma (3.0 mm, level 4) | Yes (1/4-0/1 R jugular, 1/3 R axillary) | CLND (0/5) + IFN | Alive, NED |
| F/15 | 62 | L ankle | Spitzoid melanoma (1.58 mm, level 4) | Yes (0/1) | None | Alive, NED |
| F/16 | 26 | L neck | Spitzoid melanoma (5.2 mm, level 4) | Yes (0/1) | None | Alive, NED |
| M/19 | 139 | R ear | Spitzoid melanoma (1.7 mm, level 4) | Yes (0/2) | None | Alive, NED |
| M/21 | 20 | R leg | Spitzoid melanoma (1.0 mm, level 3) | No | None | Alive, 2nd primary SSM (0.24mm, level 2) on back |
| F/29 | 218 | R calf | Spitzoid melanoma (1.8 mm, level 4) | No | None | Alive, NED |
| M/31 | 141 | R ankle | Spitzoid melanoma (2.08 mm, level 4) | Yes (0/2) | None | Alive, NED |
| M/35 | 36 | L shoulder | Minimal deviation melanoma of the Spitz type | No | None | Alive, NED |
| M/40 | 186 | L forearm | Spitzoid melanoma (2.3 mm, level 4) | Yes (2/4: 2/2 L epitrochlear node; 0/2 L axillary) | CLND (epitrochlear, no nodes) + IFN | Alive, NED |
| F/44 | 91 | L foot | Spitzoid melanoma (1.0 mm, level 3) | Yes (2/2 L groin) | CLND (0/17) + IFN | Alive, NED |
| M/17 | 113 | L thigh | SSM (0.28 mm, level 2) contiguous to a Spitz nevus | No | None | Alive, NED |
| F/27 | 148 | L scapula | NM (0.9 mm, level 3) contiguous to a Spitz nevus | No | L axilla relapse at 35 mo Treated with IFN+ Melacine a | Alive, NED |
| F/52 | 147 | R foot | SSM (0.8 mm, level 4) contiguous to a Spitz nevus | Yes (1/1 R groin) | None | Alive, NED |
Abbreviations: CLND, completion lymph node dissection; f/u, follow-up; IFN, interferon; L, left; Mel, melanoma; NED, no evidence of disease; R, right; SLNB, sentinel lymph node biopsy finding.
a
Manufactured by Corixa Corporation, Seattle, Washington.